190 related articles for article (PubMed ID: 32142920)
1. The metabolic landscape of urological cancers: New therapeutic perspectives.
Miranda-Gonçalves V; Lameirinhas A; Henrique R; Baltazar F; Jerónimo C
Cancer Lett; 2020 May; 477():76-87. PubMed ID: 32142920
[TBL] [Abstract][Full Text] [Related]
2. Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments.
Schmidt AL; Siefker-Radtke A; McConkey D; McGregor B
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32379987
[TBL] [Abstract][Full Text] [Related]
3. Molecular therapy in urologic oncology.
Froehner M; Hakenberg OW; Wirth MP
Urol Int; 2007; 79(1):1-7. PubMed ID: 17627159
[TBL] [Abstract][Full Text] [Related]
4. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract][Full Text] [Related]
5. [Systemic immune checkpoint inhibition : A promising treatment for urological tumors?].
Roos FC; Becker C; Stope MB; Tsaur I;
Urologe A; 2018 May; 57(5):583-590. PubMed ID: 29569115
[TBL] [Abstract][Full Text] [Related]
6. Present status and future perspective of peptide-based vaccine therapy for urological cancer.
Obara W; Kanehira M; Katagiri T; Kato R; Kato Y; Takata R
Cancer Sci; 2018 Mar; 109(3):550-559. PubMed ID: 29345737
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
Weiss RH
Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
[TBL] [Abstract][Full Text] [Related]
8. [The possibility of S-1 for the treatment of patients with urological cancers].
Akaza H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():236-8. PubMed ID: 16898009
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Alterations in Renal and Prostate Cancer.
Ciccarese C; Santoni M; Massari F; Modena A; Piva F; Conti A; Mazzucchelli R; Cheng L; Lopez-Beltran A; Scarpelli M; Tortora G; Montironi R
Curr Drug Metab; 2016; 17(2):150-5. PubMed ID: 26467063
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming of Metabolism in Kidney Cancer.
Wettersten HI
Semin Nephrol; 2020 Jan; 40(1):2-13. PubMed ID: 32130963
[TBL] [Abstract][Full Text] [Related]
11. Metabolic alterations in renal cell carcinoma.
Massari F; Ciccarese C; Santoni M; Brunelli M; Piva F; Modena A; Bimbatti D; Fantinel E; Santini D; Cheng L; Cascinu S; Montironi R; Tortora G
Cancer Treat Rev; 2015 Nov; 41(9):767-76. PubMed ID: 26169313
[TBL] [Abstract][Full Text] [Related]
12. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
13. Genetic and metabolic hallmarks of clear cell renal cell carcinoma.
Sanchez DJ; Simon MC
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):23-31. PubMed ID: 29959988
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Miyake H; Fujisawa M
Nihon Rinsho; 2010 Oct; 68(10):1871-5. PubMed ID: 20954332
[TBL] [Abstract][Full Text] [Related]
15. The Metabolism of Renal Cell Carcinomas and Liver Cancer.
Nguyen T; Le A
Adv Exp Med Biol; 2018; 1063():107-118. PubMed ID: 29946779
[TBL] [Abstract][Full Text] [Related]
16. Glyoxalases in Urological Malignancies.
Antognelli C; Talesa VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385039
[TBL] [Abstract][Full Text] [Related]
17. A novel approach to anticancer therapies: peroxisome proliferator activator-receptor-gamma as a new target therapy in the treatment of human urological cancer.
Matsuyama M; Yoshimura R
Endocr Metab Immune Disord Drug Targets; 2009 Mar; 9(1):76-83. PubMed ID: 19275683
[TBL] [Abstract][Full Text] [Related]
18. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
[TBL] [Abstract][Full Text] [Related]
19. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer.
Li C; Zhang G; Zhao L; Ma Z; Chen H
World J Surg Oncol; 2016 Jan; 14(1):15. PubMed ID: 26791262
[TBL] [Abstract][Full Text] [Related]
20. Biological markers in urologic cancer.
Lange PH; Winfield HN
Cancer; 1987 Aug; 60(3 Suppl):464-72. PubMed ID: 3036331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
